Identification of personalized inflammatory profiles of aging and senescence which are modified specifically by risk factors of dementia modulating the pre-dementia speed of symptomatic progression.


CALL: 2019

DOMAIN: BM - Life Sciences, Biology and Medicine

FIRST NAME: Reinhard

LAST NAME: Schneider



HOST INSTITUTION: University of Luxembourg

KEYWORDS: senescence, SASP, dementia progression, senescence-associated secretory profile, cognitive decline, Alzheimer's disease

START: 2020-01-01



Submitted Abstract

Age represents by far the highest risk factor for dementia, including Alzheimer’s disease (AD). However, not every person will develop dementia during aging, indicating that age-related processes may not inescapably lead to dementia. The elucidation of the fundamental processes occurring in aging is likely to prevent or postpone the development of dementia. One such key mechanism is cellular senescence, which causes chronic inflammation through the release senescence-associated secretory phenotype (SASP) profile of mediators. PREADAPT will build on the hypothesis that chronic systemic- and neuroinflammation, quantified through a set of SASP mediators, affects the basal trajectory of the senescence occurring in the aging brain, thus allowing to predict future cognitive decline and dementia. The levels and changes of SASP mediators during aging are modulated by different genetic and environmental factors defining thereby a personalized risk for progressing to dementia. Importantly, research has identified that SASP mediators are also altered in cerebrospinal fluid of AD patients. Moreover, SASP together with genetics, known AD biomarkers, and other comorbidities define a combined Risk Profile which provides personalized information on the risk of progressing to dementia. To achieve these goals, PREADAPT has gathered a team of leading experts in the field of neuroinflammation, epidemiology, genetics, epigenetics, neuropsychology, and clinical research. PREADAPT has access to state-of-the-art methodology and knowhow on inflammatory markers to define a set of SASP mediators which derived from PREADAPT own preliminary research. PREADAPT has also access to large epidemiological and clinical follow-up studies that are characterized in-depth using neuroimaging, genomics, and proteomics. This unique configuration will enable PREADAPT to identify, already at pre-dementia stages, age-related profiles informing on the personalized future risk to decline cognitively and to progress to dementia. From a translational perspective, PREADAPT will provide first evidence showing that a SASP personalized risk profile responds to specific intervention depending on the profile of an individuum.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement